[EN] HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS [FR] PYRROLOTRIAZINES SUBSTITUÉES PAR HYDROXYMÉTHYLARYLE UTILISÉES COMME INHIBITEURS D'ALK1
HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS
申请人:Bayer Intellectual Property GmbH
公开号:EP2726482B1
公开(公告)日:2016-07-20
US9040691B2
申请人:——
公开号:US9040691B2
公开(公告)日:2015-05-26
[EN] HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS<br/>[FR] PYRROLOTRIAZINES SUBSTITUÉES PAR HYDROXYMÉTHYLARYLE UTILISÉES COMME INHIBITEURS D'ALK1
申请人:BAYER IP GMBH
公开号:WO2013004551A1
公开(公告)日:2013-01-10
This invention relates to novel 5-[(hydroxymethyl)aryl] -substituted pyrrolo[2, 1-f][1, 2, 4] triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.
Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
申请人:Klar Jürgen
公开号:US09040691B2
公开(公告)日:2015-05-26
This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.